Catheter-Related Bloodstream Infections (CRBSIs)- Market Insights, Epidemiology, and Market Forecast-2028
This report can be delivered to the clients within 24 hours
DelveInsight’s Catheter-Related Bloodstream Infections (CRBSIs)- Market Insights, Epidemiology, and Market Forecast-2028 report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of CRBSI in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, the current and forecasted market size of CRBSI from 2017 to 2028 segmented by the seven major markets.
CRBSI refers to bloodstream infection attributed to an intravascular catheter by quantitative culture of the catheter tip or by differences in growth between catheter and peripheral venipuncture blood culture specimens. It is also known as catheter-related sepsis.
In the current scenario, there is no US Food and Drug Administration (FDA) approved drugs/lock solution present in the market, specifically for this indication, and therefore, the availability of new therapies will be the major market driver for the therapeutic market of CRBSI. Only one emerging therapy is present, which is in pipeline, i.e. Mino-Lok Therapy by Citius Pharmaceuticals. Due to non-competitiveness and poor pipeline, the launch of Mino-lok in the US or EU will create a huge hype and will have the only candidate in the CRBSI therapeutic landscape. The treatment of CRBSI is mainly preventive and is done by using off-label antibiotics. So, the need for a potential drug candidate is necessary and urgent.
Geography Covered
Catheter-Related Bloodstream Infections (CRBSIs) - Disease Understanding and Treatment Algorithm
According to “Infectious Diseases Society of America” CRBSI can be defined as bacteremia or fungemia in a patient who has an intravascular device and 11 positive blood culture result obtained from the peripheral vein, clinical manifestations of infection (e.g., fever, chills, and/or hypotension), and no apparent source for bloodstream infection (with the exception of the catheter). One of the following should be present: a positive result of semi-quantitative (>15 cfu per catheter segment) or quantitative (>102 cfu per catheter segment) catheter culture, whereby the same organism (species) is isolated from a catheter segment and a peripheral blood culture; simultaneous quantitative cultures of blood with a ratio of >3:1 cfu/mL of blood (catheter vs. peripheral blood); differential time to positivity (growth in a culture of blood obtained through a catheter hub is detected by an automated blood culture system at least 2 h earlier than a culture of simultaneously drawn peripheral blood of equal volume).
This infection is very common in ICU and non-ICU patients. Currently, there are many off label antimicrobial therapies that are recommended to treat the CRBSI. Besides considering antibiotic coverage, treatment of CRBSI consists of catheter management, with options that include removal, exchange, or salvage of the catheter. Although, salvage therapy with Intravenous antibiotics and antibiotic lock therapy (ALT) can be considered for long-term catheters, including tunneled hemodialysis catheters, in patients with limited vascular access and uncomplicated CRBSI.
Catheter-Related Bloodstream Infections (CRBSIs) – Epidemiology
The CRBSI epidemiology division provides insights about historical and current patient pool and forecasted trends for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders (KOL).
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology [segmented by Total Incident Population of CRBSI in the 7MM, Total Diagnosed Incident Population of CRBSI in the 7MM, and Diagnosed Incidence of CRBSI by Causative Pathogens in the 7MM] scenario of CRBSI in the 7MM covering United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan from 2017–2028.
As per DelveInsight’s analysis, total Incident Population of Catheter-Related Bloodstream Infection (CRBSI in the 7MM was found to be 667,753 in 2017 and expected to increase during the forecast period of 2017-2028. The estimates show the incidence was higher in the United States and among the European 5 countries, Germany had the highest incident population of CRBSI followed by France and United Kingdom. On the other hand, Spain had the lowest incident population of CRBSI.
Another estimate of Delveinsight’s analysis shows that most of the incident cases of CRBSI are confirmed with specific bacterial species. The estimates show that Gram-positive bacteria are implicated in the majority of the cases of CRBSI in comparison with Gram-negative bacteria.
Catheter-Related Bloodstream Infections (CRBSIs) – Drug Chapters
This segment of the CRBSIs report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
Neutrolin (CRMD003), is a non-antibiotic, anti-infective developed by Cormedix as a preventative solution to decrease the threat of infection and blood clots (thrombosis), thereby keeping central venous catheters (CVCs) operating safely and efficiently. It is a catheter lock solution for the prevention of catheter-related bloodstream infections (CRBSI) and maintenance of catheter patency in hemodialysis patients. It includes an anti-coagulant and broad-spectrum antimicrobial (antibacterial and antifungal) combination that is active against common microbes, including antibiotic-resistant strains, and in addition, inhibits the formation of biofilm.
TauroSept is an antimicrobial solution (lock solution) developed by Geistlich Pharma for the prevention and treatment of catheter-related infections and is intended for instillation in intravenous catheters between treatments. It mainly contains antibacterial chemotherapeutic agent taurolidine. It possesses a broader antibacterial and antimycotic spectrum of activity than any other conventional antimicrobial agents that are currently available in the market. It is also effective against methicillin-resistant and vancomycin-resistant bacteria (MRSA and VRE).
Another marketed lock solution, TauroLock was developed by TauroPharm for instillation in all central venous access systems. TauroLock catheter lock solution does not contain antibiotics and was developed for prophylactic use only. They decrease catheter-related infections significantly. It is the solution of antimicrobial and anticoagulant.
Fresenius Medical Care developed Intralock, it is also a Catheter lock solution with 4% citrate concentration, 5mL. This lock solution provides efficient coagulation prophylaxis and also minimizes the risk of systemic hypocalcemia and their consequences (cardiac arrhythmia, cardiac arrest).
Only one drug is there that is in the pipeline, which is going to be launched during the forecast period (2019–2028) i.e. Mino-lok developed by Citius Pharmaceuticals. It is an antibiotic lock solution being developed to treat patients with CLABSIs/CRBSIs. It is a combination of minocycline, edetate (disodium EDTA), and ethyl alcohol, all of which act synergistically to break down bacterial biofilms, eradicate the bacteria, provide anti-clotting properties to maintain patency in CVCs, and salvage the indwelling catheter.
Catheter-related Bloodstream Infections (CRBSIs) Market Outlook
The CRBSIs market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trends of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
The current therapeutic market of CRBSI is dependent on prevention rather than treatment and growth of market size for CRBSI is attributed to currently prescribed treatment regimens as well as emerging therapies. But due to lack of emerging therapies the market of CRBSI is depend on only one emerging therapy.
According to Delveinsight the market size of CRBSI was USD 694.7 million in 2017. The current therapeutic market of CRBSI in 7MM is driven by supportive (off-label) therapies. Among the 7MM countries, the United States accounted for highest market size for CRBSI of the total 7MM market. Among the EU-5 countries, Germany contributed the highest share towards the treatment market of CRBSI, followed by France.
Another modest increase in market size of currently prescribed therapies has been witnessed from 2017 until the launch of one and only emerging therapy for the treatment of CRBSI in respective countries, while the market share is expected to decline post that for current therapies, owing to the increasing demand for targeted therapies to treat CRBSI.
Catheter-related Bloodstream Infections (CRBSIs)– Drugs Uptake
This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017-2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.
To meet the unmet need of the market and to provide better versions of current treatment practices, the only therapy in late-stage of development being developing by Citius Pharmaceuticals (Mino-lok) for patients with CRBSI, has been anticipated to launch during our forecast period [2019–2028].
Catheter-related Bloodstream Infections Report Insights
DelveInsight’s Catheter-Related Bloodstream Infections (CRBSIs)- Market Insights, Epidemiology, and Market Forecast-2028 report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of CRBSI in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, the current and forecasted market size of CRBSI from 2017 to 2028 segmented by the seven major markets.
CRBSI refers to bloodstream infection attributed to an intravascular catheter by quantitative culture of the catheter tip or by differences in growth between catheter and peripheral venipuncture blood culture specimens. It is also known as catheter-related sepsis.
In the current scenario, there is no US Food and Drug Administration (FDA) approved drugs/lock solution present in the market, specifically for this indication, and therefore, the availability of new therapies will be the major market driver for the therapeutic market of CRBSI. Only one emerging therapy is present, which is in pipeline, i.e. Mino-Lok Therapy by Citius Pharmaceuticals. Due to non-competitiveness and poor pipeline, the launch of Mino-lok in the US or EU will create a huge hype and will have the only candidate in the CRBSI therapeutic landscape. The treatment of CRBSI is mainly preventive and is done by using off-label antibiotics. So, the need for a potential drug candidate is necessary and urgent.
Geography Covered
- The United States
- EU5 (Germany, France, Italy, Spain, and the United Kingdom)
- Japan
Catheter-Related Bloodstream Infections (CRBSIs) - Disease Understanding and Treatment Algorithm
According to “Infectious Diseases Society of America” CRBSI can be defined as bacteremia or fungemia in a patient who has an intravascular device and 11 positive blood culture result obtained from the peripheral vein, clinical manifestations of infection (e.g., fever, chills, and/or hypotension), and no apparent source for bloodstream infection (with the exception of the catheter). One of the following should be present: a positive result of semi-quantitative (>15 cfu per catheter segment) or quantitative (>102 cfu per catheter segment) catheter culture, whereby the same organism (species) is isolated from a catheter segment and a peripheral blood culture; simultaneous quantitative cultures of blood with a ratio of >3:1 cfu/mL of blood (catheter vs. peripheral blood); differential time to positivity (growth in a culture of blood obtained through a catheter hub is detected by an automated blood culture system at least 2 h earlier than a culture of simultaneously drawn peripheral blood of equal volume).
This infection is very common in ICU and non-ICU patients. Currently, there are many off label antimicrobial therapies that are recommended to treat the CRBSI. Besides considering antibiotic coverage, treatment of CRBSI consists of catheter management, with options that include removal, exchange, or salvage of the catheter. Although, salvage therapy with Intravenous antibiotics and antibiotic lock therapy (ALT) can be considered for long-term catheters, including tunneled hemodialysis catheters, in patients with limited vascular access and uncomplicated CRBSI.
Catheter-Related Bloodstream Infections (CRBSIs) – Epidemiology
The CRBSI epidemiology division provides insights about historical and current patient pool and forecasted trends for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders (KOL).
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology [segmented by Total Incident Population of CRBSI in the 7MM, Total Diagnosed Incident Population of CRBSI in the 7MM, and Diagnosed Incidence of CRBSI by Causative Pathogens in the 7MM] scenario of CRBSI in the 7MM covering United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan from 2017–2028.
As per DelveInsight’s analysis, total Incident Population of Catheter-Related Bloodstream Infection (CRBSI in the 7MM was found to be 667,753 in 2017 and expected to increase during the forecast period of 2017-2028. The estimates show the incidence was higher in the United States and among the European 5 countries, Germany had the highest incident population of CRBSI followed by France and United Kingdom. On the other hand, Spain had the lowest incident population of CRBSI.
Another estimate of Delveinsight’s analysis shows that most of the incident cases of CRBSI are confirmed with specific bacterial species. The estimates show that Gram-positive bacteria are implicated in the majority of the cases of CRBSI in comparison with Gram-negative bacteria.
Catheter-Related Bloodstream Infections (CRBSIs) – Drug Chapters
This segment of the CRBSIs report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
Neutrolin (CRMD003), is a non-antibiotic, anti-infective developed by Cormedix as a preventative solution to decrease the threat of infection and blood clots (thrombosis), thereby keeping central venous catheters (CVCs) operating safely and efficiently. It is a catheter lock solution for the prevention of catheter-related bloodstream infections (CRBSI) and maintenance of catheter patency in hemodialysis patients. It includes an anti-coagulant and broad-spectrum antimicrobial (antibacterial and antifungal) combination that is active against common microbes, including antibiotic-resistant strains, and in addition, inhibits the formation of biofilm.
TauroSept is an antimicrobial solution (lock solution) developed by Geistlich Pharma for the prevention and treatment of catheter-related infections and is intended for instillation in intravenous catheters between treatments. It mainly contains antibacterial chemotherapeutic agent taurolidine. It possesses a broader antibacterial and antimycotic spectrum of activity than any other conventional antimicrobial agents that are currently available in the market. It is also effective against methicillin-resistant and vancomycin-resistant bacteria (MRSA and VRE).
Another marketed lock solution, TauroLock was developed by TauroPharm for instillation in all central venous access systems. TauroLock catheter lock solution does not contain antibiotics and was developed for prophylactic use only. They decrease catheter-related infections significantly. It is the solution of antimicrobial and anticoagulant.
Fresenius Medical Care developed Intralock, it is also a Catheter lock solution with 4% citrate concentration, 5mL. This lock solution provides efficient coagulation prophylaxis and also minimizes the risk of systemic hypocalcemia and their consequences (cardiac arrhythmia, cardiac arrest).
Only one drug is there that is in the pipeline, which is going to be launched during the forecast period (2019–2028) i.e. Mino-lok developed by Citius Pharmaceuticals. It is an antibiotic lock solution being developed to treat patients with CLABSIs/CRBSIs. It is a combination of minocycline, edetate (disodium EDTA), and ethyl alcohol, all of which act synergistically to break down bacterial biofilms, eradicate the bacteria, provide anti-clotting properties to maintain patency in CVCs, and salvage the indwelling catheter.
Catheter-related Bloodstream Infections (CRBSIs) Market Outlook
The CRBSIs market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trends of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
The current therapeutic market of CRBSI is dependent on prevention rather than treatment and growth of market size for CRBSI is attributed to currently prescribed treatment regimens as well as emerging therapies. But due to lack of emerging therapies the market of CRBSI is depend on only one emerging therapy.
According to Delveinsight the market size of CRBSI was USD 694.7 million in 2017. The current therapeutic market of CRBSI in 7MM is driven by supportive (off-label) therapies. Among the 7MM countries, the United States accounted for highest market size for CRBSI of the total 7MM market. Among the EU-5 countries, Germany contributed the highest share towards the treatment market of CRBSI, followed by France.
Another modest increase in market size of currently prescribed therapies has been witnessed from 2017 until the launch of one and only emerging therapy for the treatment of CRBSI in respective countries, while the market share is expected to decline post that for current therapies, owing to the increasing demand for targeted therapies to treat CRBSI.
Catheter-related Bloodstream Infections (CRBSIs)– Drugs Uptake
This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017-2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.
To meet the unmet need of the market and to provide better versions of current treatment practices, the only therapy in late-stage of development being developing by Citius Pharmaceuticals (Mino-lok) for patients with CRBSI, has been anticipated to launch during our forecast period [2019–2028].
Catheter-related Bloodstream Infections Report Insights
- Patient Population
- Therapeutic Approaches
- Pipeline Analysis
- Market Size and Trends
- Market Opportunities
- Impact of upcoming Therapies
- 10 Year Forecast
- 7MM Coverage
- Epidemiology Segmentation
- Drugs Uptake
- Highly Analyzed Market
- Key Cross Competition
- Current Treatment Practices
- Unmet Needs
- Detailed Pipeline Product Profiles
- Market Attractiveness
- Market Drivers and Barriers
- This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving Catheter-related Bloodstream Infections (CRBSIs) market
- Organize sales and marketing efforts by identifying the best opportunities for CRBSI market
- To understand the future market competition in the CRBSI market.
1. KEY INSIGHTS
2. CATHETER-RELATED BLOOD STREAM INFECTION (CRBSI) MARKET OVERVIEW AT A GLANCE
2.1. Total Market Share (%) Distribution of CRBSI in 2017
2.2. Total Market Share (%) Distribution of CRBSI in 2028
3. CATHETER-RELATED BLOODSTREAM INFECTION (CRBSI): DISEASE BACKGROUND AND OVERVIEW
3.1. Introduction
3.2. Difference between CLABSI and CRBSI
3.3. Causes of Catheter-Related Bloodstream Infection (CRBSI)
3.3.1. Micro-organisms
3.3.2. Intravascular Devices
3.4. Risk Factor Associated with Catheter-Related Bloodstream Infection (CRBSI)
3.5. Pathogenesis of Catheter-Related Bloodstream Infection (CRBSI)
3.6. Diagnosis of Catheter-Related Bloodstream Infection (CRBSI)
3.7. Diagnosis Guidelines Catheter-Related Bloodstream Infection (CRBSI)
3.7.1. Infectious Diseases Society of America (IDSA) Guidelines for CRBSI
3.7.2. Spanish Society of Infectious Diseases and Clinical Microbiology and (SEIMC) and the Spanish Society of Intensive and Critical Care Medicine and Coronary Units (SEMICYUC)
3.7.3. British Intestinal Failure Alliance (BIFA):
3.7.4. European Renal Best Practice (ERBP) Recommendations for Diagnosis of CRBSIs
4. EPIDEMIOLOGY AND PATIENT POPULATION
4.1. Key Findings
4.2. Total Incident Population of CRBSI in the 7MM
4.3. Total Diagnosed Incident Population of CRBSI in the 7MM
4.4. Diagnosed Incidence of CRBSI by Causative Pathogens in the 7MM
4.5. Some KOL Insights
5. UNITED STATES EPIDEMIOLOGY
5.1. Assumptions and Rationale
5.2. Total Incident Population of CRBSI in the United States
5.3. Total Diagnosed Incident Population of CRBSI in the United States
5.4. Diagnosed Incidence of CRBSI by Causative Pathogens in the United States
6. EU5 EPIDEMIOLOGY
6.1. Germany Epidemiology
6.1.1. Assumptions and Rationale
6.1.2. Total Incident Population of CRBSI in Germany
6.1.3. Total Diagnosed Incident Population of CRBSI in Germany
6.1.4. Diagnosed Incidence of CRBSI by Causative Pathogens in Germany
6.2. France Epidemiology
6.2.1. Assumptions and rationale
6.2.2. Total Incident Population of CRBSI in France
6.2.3. Total Diagnosed Incident Population of CRBSI in France
6.2.4. Diagnosed Incidence of CRBSI by Causative Pathogens in France
6.3. Italy Epidemiology
6.3.1. Assumptions and Rationale
6.3.2. Total Incident Population of CRBSI in Italy
6.3.3. Total Diagnosed Incident Population of CRBSI in Italy
6.3.4. Diagnosed Incidence of CRBSI by Causative Pathogens in Italy
6.4. Spain Epidemiology
6.4.1. Assumptions and Rationale
6.4.2. Total Incident Population of CRBSI in Spain
6.4.3. Total Diagnosed Incident Population of CRBSI in Spain
6.4.4. Diagnosed Incidence of CRBSI by Causative Pathogens in Spain
6.5. United Kingdom Epidemiology
6.5.1. Assumptions and Rationale
6.5.2. Total Incident Population of CRBSI in the United Kingdom
6.5.3. Total Diagnosed Incident Population of CRBSI in the United Kingdom
6.5.4. Diagnosed Incidence of CRBSI by Causative Pathogens in the United Kingdom
7. JAPAN EPIDEMIOLOGY
7.1. Assumptions and Rationale
7.2. Total Incident Population of CRBSI in Japan
7.3. Total Diagnosed Incident Population of CRBSI in Japan
7.4. Diagnosed Incidence of CRBSI by Causative Pathogens in Japan
8. TOTAL TREATMENT ALGORITHM, CURRENT TREATMENT, AND MEDICAL PRACTICES
8.1. Treatment of Catheter-Related Bloodstream Infection (CRBSI)
8.1.1. General
8.1.2. Short-term Central Venous or Arterial CRBSI
8.1.3. Long-term Central Venous CRBSI
8.2. Treatment Guidelines for Catheter-related bloodstream infection (CRBSI)
8.2.1. Infectious Diseases Society of America: Guidelines for the pathogen-specific treatment
8.2.2. Spanish Society of Infectious Diseases: Treatment of CRBSIs
8.3. Prevention Guidelines of Catheter-Related Bloodstream Infection (CRBSI)
8.3.1. Infectious Diseases Society of America (IDSA), Healthcare Infection Control Practices Advisory Committee (HICPAC) of the Centers for Disease Control and Prevention (CDC):
8.3.2. European Renal Best Practice (ERBP) Recommendations for Prevention of CRBSIs
9. UNMET NEEDS
10. MARKETED PRODUCTS
10.1. Neutrolin: CorMedix
10.1.1. Product Description
10.1.2. Mechanism of Action
10.1.3. Regulatory milestones
10.1.4. Clinical Development
10.1.5. Clinical Trials Information
10.1.6. Safety and Efficacy
10.1.7. Product Profile
10.2. Taurosept: Geistlich Pharma
10.2.1. Product Description
10.2.2. Mechanism of Action
10.2.3. Regulatory milestones
10.2.4. Clinical Development
10.2.5. Safety and Efficacy
10.2.6. Product Profile
10.3. Taurolock: TauroPharm GmbH
10.3.1. Product Description
10.3.2. Mechanism of Action
10.3.3. Regulatory Milestones
10.3.4. Clinical Development
10.3.5. Clinical Trials Information
10.3.6. Safety and Efficacy
10.3.7. Product Profile
10.4. IntraLock: Fresenius Medical Care
10.4.1. Product Description
10.4.2. Mechanism of Action
10.4.3. Regulatory Milestones
10.4.4. Advantages
10.4.5. Product Profile
11. OFF-LABEL DRUGS
11.1. Antibacterials
11.1.1. Daptomycin
11.1.1.1. Product Description
11.1.1.2. Mechanism of Action
11.1.1.3. Generic Availability
11.1.1.4. Clinical Trials Information
11.1.2. Vancomycin
11.1.2.1. Product Description
11.1.2.2. Mechanism of Action
11.1.2.3. Generic Availability
11.1.3. Cefazolin
11.1.3.1. Product Description
11.1.3.2. Mechanism of Action
11.1.3.3. Generic Availability
11.1.4. Ampicillin
11.1.4.1. Product Description
11.1.4.2. Mechanism of Action
11.1.4.3. Generic Availability
11.1.5. Ciprofloxacin
11.1.5.1. Product Description
11.1.5.2. Mechanism of Action
11.1.5.3. Generic Availability
11.1.6. Amikacin
11.1.6.1. Product Description
11.1.6.2. Mechanism of Action
11.1.6.3. Generic Availability
11.1.7. Teicoplanin
11.1.7.1. Product Description
11.1.7.2. Mechanism of Action
11.1.7.3. Generic Availability
11.2. Antifungals
11.2.1. Fluconazole
11.2.1.1. Product Description
11.2.1.2. Mechanism of Action
11.2.1.3. Generic Availability
11.2.2. Amphotericin B
11.2.2.1. Product Description
11.2.2.2. Mechanism of Action
11.2.2.3. Generic Availability
12. EMERGING THERAPIES
12.1. Mino-Lok: Citius Pharmaceuticals
12.1.1. Product Description
12.1.2. Other Developmental Activities
12.1.3. Clinical Development
12.1.4. Product Profile
13. CRBSI: 7MM MARKET ANALYSIS
13.1. Key Findings
13.2. Market Size of CRBSI in 7MM
13.3. Market Size of CRBSI by Therapies in the 7MM
14. UNITED STATES: MARKET OUTLOOK
14.1. United States Market Size
14.1.1. Total Market size of CRBSI
14.1.2. Market Size of CRBSI by Therapies in the US
15. EU-5 COUNTRIES: MARKET OUTLOOK
15.1. Germany Market Size
15.1.1. Total Market size of CRBSI
15.1.2. Market Size of CRBSI by therapies in Germany
15.2. France Market Size
15.2.1. Total Market size of CRBSI
15.2.2. Market Size of CRBSI by therapies in France
15.3. Italy Market Size
15.3.1. Total Market size of CRBSI
15.3.2. Market Size of CRBSI by therapies in Italy
15.4. Spain Market Size
15.4.1. Total Market size of CRBSI
15.4.2. Market Size of CRBSI by therapies in Spain
15.5. United Kingdom Market Size
15.5.1. Total Market size of CRBSI
15.5.2. Market Size of CRBSI by therapies in the UK
16. JAPAN MARKET OUTLOOK
16.1. Japan Market Size
16.1.1. Total Market size of CRBSI
16.1.2. Market Size of CRBSI by therapies in Japan
17. MARKET DRIVERS
18. MARKET BARRIERS
19. APPENDIX
19.1. Report Methodology
20. DELVEINSIGHT CAPABILITIES
21. DISCLAIMER
22. ABOUT DELVEINSIGHT
2. CATHETER-RELATED BLOOD STREAM INFECTION (CRBSI) MARKET OVERVIEW AT A GLANCE
2.1. Total Market Share (%) Distribution of CRBSI in 2017
2.2. Total Market Share (%) Distribution of CRBSI in 2028
3. CATHETER-RELATED BLOODSTREAM INFECTION (CRBSI): DISEASE BACKGROUND AND OVERVIEW
3.1. Introduction
3.2. Difference between CLABSI and CRBSI
3.3. Causes of Catheter-Related Bloodstream Infection (CRBSI)
3.3.1. Micro-organisms
3.3.2. Intravascular Devices
3.4. Risk Factor Associated with Catheter-Related Bloodstream Infection (CRBSI)
3.5. Pathogenesis of Catheter-Related Bloodstream Infection (CRBSI)
3.6. Diagnosis of Catheter-Related Bloodstream Infection (CRBSI)
3.7. Diagnosis Guidelines Catheter-Related Bloodstream Infection (CRBSI)
3.7.1. Infectious Diseases Society of America (IDSA) Guidelines for CRBSI
3.7.2. Spanish Society of Infectious Diseases and Clinical Microbiology and (SEIMC) and the Spanish Society of Intensive and Critical Care Medicine and Coronary Units (SEMICYUC)
3.7.3. British Intestinal Failure Alliance (BIFA):
3.7.4. European Renal Best Practice (ERBP) Recommendations for Diagnosis of CRBSIs
4. EPIDEMIOLOGY AND PATIENT POPULATION
4.1. Key Findings
4.2. Total Incident Population of CRBSI in the 7MM
4.3. Total Diagnosed Incident Population of CRBSI in the 7MM
4.4. Diagnosed Incidence of CRBSI by Causative Pathogens in the 7MM
4.5. Some KOL Insights
5. UNITED STATES EPIDEMIOLOGY
5.1. Assumptions and Rationale
5.2. Total Incident Population of CRBSI in the United States
5.3. Total Diagnosed Incident Population of CRBSI in the United States
5.4. Diagnosed Incidence of CRBSI by Causative Pathogens in the United States
6. EU5 EPIDEMIOLOGY
6.1. Germany Epidemiology
6.1.1. Assumptions and Rationale
6.1.2. Total Incident Population of CRBSI in Germany
6.1.3. Total Diagnosed Incident Population of CRBSI in Germany
6.1.4. Diagnosed Incidence of CRBSI by Causative Pathogens in Germany
6.2. France Epidemiology
6.2.1. Assumptions and rationale
6.2.2. Total Incident Population of CRBSI in France
6.2.3. Total Diagnosed Incident Population of CRBSI in France
6.2.4. Diagnosed Incidence of CRBSI by Causative Pathogens in France
6.3. Italy Epidemiology
6.3.1. Assumptions and Rationale
6.3.2. Total Incident Population of CRBSI in Italy
6.3.3. Total Diagnosed Incident Population of CRBSI in Italy
6.3.4. Diagnosed Incidence of CRBSI by Causative Pathogens in Italy
6.4. Spain Epidemiology
6.4.1. Assumptions and Rationale
6.4.2. Total Incident Population of CRBSI in Spain
6.4.3. Total Diagnosed Incident Population of CRBSI in Spain
6.4.4. Diagnosed Incidence of CRBSI by Causative Pathogens in Spain
6.5. United Kingdom Epidemiology
6.5.1. Assumptions and Rationale
6.5.2. Total Incident Population of CRBSI in the United Kingdom
6.5.3. Total Diagnosed Incident Population of CRBSI in the United Kingdom
6.5.4. Diagnosed Incidence of CRBSI by Causative Pathogens in the United Kingdom
7. JAPAN EPIDEMIOLOGY
7.1. Assumptions and Rationale
7.2. Total Incident Population of CRBSI in Japan
7.3. Total Diagnosed Incident Population of CRBSI in Japan
7.4. Diagnosed Incidence of CRBSI by Causative Pathogens in Japan
8. TOTAL TREATMENT ALGORITHM, CURRENT TREATMENT, AND MEDICAL PRACTICES
8.1. Treatment of Catheter-Related Bloodstream Infection (CRBSI)
8.1.1. General
8.1.2. Short-term Central Venous or Arterial CRBSI
8.1.3. Long-term Central Venous CRBSI
8.2. Treatment Guidelines for Catheter-related bloodstream infection (CRBSI)
8.2.1. Infectious Diseases Society of America: Guidelines for the pathogen-specific treatment
8.2.2. Spanish Society of Infectious Diseases: Treatment of CRBSIs
8.3. Prevention Guidelines of Catheter-Related Bloodstream Infection (CRBSI)
8.3.1. Infectious Diseases Society of America (IDSA), Healthcare Infection Control Practices Advisory Committee (HICPAC) of the Centers for Disease Control and Prevention (CDC):
8.3.2. European Renal Best Practice (ERBP) Recommendations for Prevention of CRBSIs
9. UNMET NEEDS
10. MARKETED PRODUCTS
10.1. Neutrolin: CorMedix
10.1.1. Product Description
10.1.2. Mechanism of Action
10.1.3. Regulatory milestones
10.1.4. Clinical Development
10.1.5. Clinical Trials Information
10.1.6. Safety and Efficacy
10.1.7. Product Profile
10.2. Taurosept: Geistlich Pharma
10.2.1. Product Description
10.2.2. Mechanism of Action
10.2.3. Regulatory milestones
10.2.4. Clinical Development
10.2.5. Safety and Efficacy
10.2.6. Product Profile
10.3. Taurolock: TauroPharm GmbH
10.3.1. Product Description
10.3.2. Mechanism of Action
10.3.3. Regulatory Milestones
10.3.4. Clinical Development
10.3.5. Clinical Trials Information
10.3.6. Safety and Efficacy
10.3.7. Product Profile
10.4. IntraLock: Fresenius Medical Care
10.4.1. Product Description
10.4.2. Mechanism of Action
10.4.3. Regulatory Milestones
10.4.4. Advantages
10.4.5. Product Profile
11. OFF-LABEL DRUGS
11.1. Antibacterials
11.1.1. Daptomycin
11.1.1.1. Product Description
11.1.1.2. Mechanism of Action
11.1.1.3. Generic Availability
11.1.1.4. Clinical Trials Information
11.1.2. Vancomycin
11.1.2.1. Product Description
11.1.2.2. Mechanism of Action
11.1.2.3. Generic Availability
11.1.3. Cefazolin
11.1.3.1. Product Description
11.1.3.2. Mechanism of Action
11.1.3.3. Generic Availability
11.1.4. Ampicillin
11.1.4.1. Product Description
11.1.4.2. Mechanism of Action
11.1.4.3. Generic Availability
11.1.5. Ciprofloxacin
11.1.5.1. Product Description
11.1.5.2. Mechanism of Action
11.1.5.3. Generic Availability
11.1.6. Amikacin
11.1.6.1. Product Description
11.1.6.2. Mechanism of Action
11.1.6.3. Generic Availability
11.1.7. Teicoplanin
11.1.7.1. Product Description
11.1.7.2. Mechanism of Action
11.1.7.3. Generic Availability
11.2. Antifungals
11.2.1. Fluconazole
11.2.1.1. Product Description
11.2.1.2. Mechanism of Action
11.2.1.3. Generic Availability
11.2.2. Amphotericin B
11.2.2.1. Product Description
11.2.2.2. Mechanism of Action
11.2.2.3. Generic Availability
12. EMERGING THERAPIES
12.1. Mino-Lok: Citius Pharmaceuticals
12.1.1. Product Description
12.1.2. Other Developmental Activities
12.1.3. Clinical Development
12.1.4. Product Profile
13. CRBSI: 7MM MARKET ANALYSIS
13.1. Key Findings
13.2. Market Size of CRBSI in 7MM
13.3. Market Size of CRBSI by Therapies in the 7MM
14. UNITED STATES: MARKET OUTLOOK
14.1. United States Market Size
14.1.1. Total Market size of CRBSI
14.1.2. Market Size of CRBSI by Therapies in the US
15. EU-5 COUNTRIES: MARKET OUTLOOK
15.1. Germany Market Size
15.1.1. Total Market size of CRBSI
15.1.2. Market Size of CRBSI by therapies in Germany
15.2. France Market Size
15.2.1. Total Market size of CRBSI
15.2.2. Market Size of CRBSI by therapies in France
15.3. Italy Market Size
15.3.1. Total Market size of CRBSI
15.3.2. Market Size of CRBSI by therapies in Italy
15.4. Spain Market Size
15.4.1. Total Market size of CRBSI
15.4.2. Market Size of CRBSI by therapies in Spain
15.5. United Kingdom Market Size
15.5.1. Total Market size of CRBSI
15.5.2. Market Size of CRBSI by therapies in the UK
16. JAPAN MARKET OUTLOOK
16.1. Japan Market Size
16.1.1. Total Market size of CRBSI
16.1.2. Market Size of CRBSI by therapies in Japan
17. MARKET DRIVERS
18. MARKET BARRIERS
19. APPENDIX
19.1. Report Methodology
20. DELVEINSIGHT CAPABILITIES
21. DISCLAIMER
22. ABOUT DELVEINSIGHT
LIST OF TABLES
TABLE 1: TERMINOLOGY: CLABSI OR CRBSI
TABLE 2: VARIOUS RISK FACTORS OF CRBSI
TABLE 3: TOTAL INCIDENT POPULATION OF CRBSI IN THE 7MM (2017–2028)
TABLE 4: TOTAL DIAGNOSED INCIDENT POPULATION OF CRBSI IN THE 7MM (2017–2028)
TABLE 5: DIAGNOSED INCIDENCE OF CRBSI BY CAUSATIVE PATHOGENS IN THE 7MM (2017–2028)
TABLE 6: TOTAL INCIDENT POPULATION OF CRBSI IN THE US (2017–2028)
TABLE 7: TOTAL DIAGNOSED INCIDENT POPULATION OF CRBSI IN THE US (2017–2028)
TABLE 8: DIAGNOSED INCIDENCE OF CRBSI BY CAUSATIVE PATHOGENS IN THE US (2017–2028)
TABLE 9: TOTAL INCIDENT POPULATION OF CRBSI IN GERMANY (2017–2028)
TABLE 10: TOTAL DIAGNOSED INCIDENT POPULATION OF CRBSI IN GERMANY (2017–2028)
TABLE 11: DIAGNOSED INCIDENCE OF CRBSI BY CAUSATIVE PATHOGENS IN GERMANY (2017–2028)
TABLE 12: TOTAL INCIDENT POPULATION OF CRBSI IN FRANCE (2017–2028)
TABLE 13: TOTAL DIAGNOSED INCIDENT POPULATION OF CRBSI IN FRANCE (2017–2028)
TABLE 14: DIAGNOSED INCIDENCE OF CRBSI BY CAUSATIVE PATHOGENS IN FRANCE (2017–2028)
TABLE 15: TOTAL INCIDENT POPULATION OF CRBSI IN ITALY (2017–2028)
TABLE 16: TOTAL DIAGNOSED INCIDENT POPULATION OF CRBSI IN ITALY (2017–2028)
TABLE 17: DIAGNOSED INCIDENCE OF CRBSI BY CAUSATIVE PATHOGENS IN ITALY (2017–2028)
TABLE 18: TOTAL INCIDENT POPULATION OF CRBSI IN SPAIN (2017–2028)
TABLE 19: TOTAL DIAGNOSED INCIDENT POPULATION OF CRBSI IN SPAIN (2017–2028)
TABLE 20: DIAGNOSED INCIDENCE OF CRBSI BY CAUSATIVE PATHOGENS IN SPAIN (2017–2028)
TABLE 21: TOTAL INCIDENT POPULATION OF CRBSI IN THE UK (2017–2028)
TABLE 22: TOTAL DIAGNOSED INCIDENT POPULATION OF CRBSI IN THE UK (2017–2028)
TABLE 23: DIAGNOSED INCIDENCE OF CRBSI BY CAUSATIVE PATHOGENS IN THE UK (2017–2028)
TABLE 24: TOTAL INCIDENT POPULATION OF CRBSI IN THE JAPAN (2017–2028)
TABLE 25: TOTAL DIAGNOSED INCIDENT POPULATION OF CRBSI IN THE JAPAN (2017–2028)
TABLE 26: DIAGNOSED INCIDENCE OF CRBSI BY CAUSATIVE PATHOGENS IN JAPAN (2017–2028)
TABLE 27: THE MAIN ANTIMICROBIAL DRUG AND DOSAGE REGIMENS THAT SHOULD BE USED FOR CATHETER-RELATED INFECTIONS.
TABLE 28: NEUTROLIN (CRMD003), CLINICAL TRIAL DESCRIPTION, 2019
TABLE 29: TAUROSEPT, CLINICAL TRIAL DESCRIPTION, 2019
TABLE 30: TAUROLOCK, CLINICAL TRIAL DESCRIPTION, 2019
TABLE 31: GENERIC PRODUCTS OF DAPTOMYCIN IN THE 7MM
TABLE 32: DAPTOMYCIN, CLINICAL TRIAL DESCRIPTION, 2019
TABLE 33: GENERIC PRODUCTS OF VANCOMYCIN IN THE 7MM
TABLE 34: GENERIC PRODUCTS OF CEFAZOLIN IN THE 7MM
TABLE 35: GENERIC PRODUCTS OF AMPICILLIN IN THE 7MM
TABLE 36: GENERIC PRODUCTS OF CIPROFLOXACIN AVAILABLE IN THE 7MM
TABLE 37: GENERIC PRODUCTS OF AMIKACIN IN THE 7MM
TABLE 38: GENERIC PRODUCTS OF TEICOPLANIN IN THE 7MM
TABLE 39: GENERIC PRODUCTS OF FLUCONAZOLE IN THE 7MM
TABLE 40: GENERIC PRODUCTS OF AMPHOTERICIN B IN THE 7MM
TABLE 41: MINO-LOK, CLINICAL TRIAL DESCRIPTION, 2019
TABLE 42: MARKET SIZE OF CATHETER RELATED BLOODSTREAM INFECTION (CRBSI) IN THE 7MM IN USD MILLION (2017–2028)
TABLE 43: MARKET SIZE OF CRBSI BY THERAPIES IN THE 7MM, IN USD MILLION (2017–2028)
TABLE 44: THE US MARKET SIZE OF CRBSI IN USD MILLION (2017–2028)
TABLE 45: MARKET SIZE OF CRBSI BY THERAPIES IN THE UNITED STATES, IN USD MILLION (2017–2028)
TABLE 46: GERMANY MARKET SIZE OF CRBSI IN USD MILLION (2017–2028)
TABLE 47: MARKET SIZE OF CRBSI BY THERAPIES IN GERMANY, IN USD MILLION (2017–2028)
TABLE 48: FRANCE MARKET SIZE OF CRBSI IN USD MILLION (2017–2028)
TABLE 49: MARKET SIZE OF CRBSI BY THERAPIES IN FRANCE, IN USD MILLION (2017–2028)
TABLE 50: ITALY MARKET SIZE OF CRBSI IN USD MILLION (2017–2028)
TABLE 51: MARKET SIZE OF CRBSI BY THERAPIES IN ITALY, IN USD MILLION (2017–2028)
TABLE 52: SPAIN MARKET SIZE OF CRBSI IN USD MILLION (2017–2028)
TABLE 53: MARKET SIZE OF CRBSI BY THERAPIES IN SPAIN, IN USD MILLION (2017–2028)
TABLE 54: THE UK MARKET SIZE OF CRBSI IN USD MILLION (2017–2028)
TABLE 55: MARKET SIZE OF CRBSI BY THERAPIES IN THE UK, IN USD MILLION (2017–2028)
TABLE 56: JAPAN MARKET SIZE OF CRBSI IN USD MILLION (2017–2028)
TABLE 57: MARKET SIZE OF CRBSI BY THERAPIES IN THE JAPAN, IN USD MILLION (2017–2028)
TABLE 1: TERMINOLOGY: CLABSI OR CRBSI
TABLE 2: VARIOUS RISK FACTORS OF CRBSI
TABLE 3: TOTAL INCIDENT POPULATION OF CRBSI IN THE 7MM (2017–2028)
TABLE 4: TOTAL DIAGNOSED INCIDENT POPULATION OF CRBSI IN THE 7MM (2017–2028)
TABLE 5: DIAGNOSED INCIDENCE OF CRBSI BY CAUSATIVE PATHOGENS IN THE 7MM (2017–2028)
TABLE 6: TOTAL INCIDENT POPULATION OF CRBSI IN THE US (2017–2028)
TABLE 7: TOTAL DIAGNOSED INCIDENT POPULATION OF CRBSI IN THE US (2017–2028)
TABLE 8: DIAGNOSED INCIDENCE OF CRBSI BY CAUSATIVE PATHOGENS IN THE US (2017–2028)
TABLE 9: TOTAL INCIDENT POPULATION OF CRBSI IN GERMANY (2017–2028)
TABLE 10: TOTAL DIAGNOSED INCIDENT POPULATION OF CRBSI IN GERMANY (2017–2028)
TABLE 11: DIAGNOSED INCIDENCE OF CRBSI BY CAUSATIVE PATHOGENS IN GERMANY (2017–2028)
TABLE 12: TOTAL INCIDENT POPULATION OF CRBSI IN FRANCE (2017–2028)
TABLE 13: TOTAL DIAGNOSED INCIDENT POPULATION OF CRBSI IN FRANCE (2017–2028)
TABLE 14: DIAGNOSED INCIDENCE OF CRBSI BY CAUSATIVE PATHOGENS IN FRANCE (2017–2028)
TABLE 15: TOTAL INCIDENT POPULATION OF CRBSI IN ITALY (2017–2028)
TABLE 16: TOTAL DIAGNOSED INCIDENT POPULATION OF CRBSI IN ITALY (2017–2028)
TABLE 17: DIAGNOSED INCIDENCE OF CRBSI BY CAUSATIVE PATHOGENS IN ITALY (2017–2028)
TABLE 18: TOTAL INCIDENT POPULATION OF CRBSI IN SPAIN (2017–2028)
TABLE 19: TOTAL DIAGNOSED INCIDENT POPULATION OF CRBSI IN SPAIN (2017–2028)
TABLE 20: DIAGNOSED INCIDENCE OF CRBSI BY CAUSATIVE PATHOGENS IN SPAIN (2017–2028)
TABLE 21: TOTAL INCIDENT POPULATION OF CRBSI IN THE UK (2017–2028)
TABLE 22: TOTAL DIAGNOSED INCIDENT POPULATION OF CRBSI IN THE UK (2017–2028)
TABLE 23: DIAGNOSED INCIDENCE OF CRBSI BY CAUSATIVE PATHOGENS IN THE UK (2017–2028)
TABLE 24: TOTAL INCIDENT POPULATION OF CRBSI IN THE JAPAN (2017–2028)
TABLE 25: TOTAL DIAGNOSED INCIDENT POPULATION OF CRBSI IN THE JAPAN (2017–2028)
TABLE 26: DIAGNOSED INCIDENCE OF CRBSI BY CAUSATIVE PATHOGENS IN JAPAN (2017–2028)
TABLE 27: THE MAIN ANTIMICROBIAL DRUG AND DOSAGE REGIMENS THAT SHOULD BE USED FOR CATHETER-RELATED INFECTIONS.
TABLE 28: NEUTROLIN (CRMD003), CLINICAL TRIAL DESCRIPTION, 2019
TABLE 29: TAUROSEPT, CLINICAL TRIAL DESCRIPTION, 2019
TABLE 30: TAUROLOCK, CLINICAL TRIAL DESCRIPTION, 2019
TABLE 31: GENERIC PRODUCTS OF DAPTOMYCIN IN THE 7MM
TABLE 32: DAPTOMYCIN, CLINICAL TRIAL DESCRIPTION, 2019
TABLE 33: GENERIC PRODUCTS OF VANCOMYCIN IN THE 7MM
TABLE 34: GENERIC PRODUCTS OF CEFAZOLIN IN THE 7MM
TABLE 35: GENERIC PRODUCTS OF AMPICILLIN IN THE 7MM
TABLE 36: GENERIC PRODUCTS OF CIPROFLOXACIN AVAILABLE IN THE 7MM
TABLE 37: GENERIC PRODUCTS OF AMIKACIN IN THE 7MM
TABLE 38: GENERIC PRODUCTS OF TEICOPLANIN IN THE 7MM
TABLE 39: GENERIC PRODUCTS OF FLUCONAZOLE IN THE 7MM
TABLE 40: GENERIC PRODUCTS OF AMPHOTERICIN B IN THE 7MM
TABLE 41: MINO-LOK, CLINICAL TRIAL DESCRIPTION, 2019
TABLE 42: MARKET SIZE OF CATHETER RELATED BLOODSTREAM INFECTION (CRBSI) IN THE 7MM IN USD MILLION (2017–2028)
TABLE 43: MARKET SIZE OF CRBSI BY THERAPIES IN THE 7MM, IN USD MILLION (2017–2028)
TABLE 44: THE US MARKET SIZE OF CRBSI IN USD MILLION (2017–2028)
TABLE 45: MARKET SIZE OF CRBSI BY THERAPIES IN THE UNITED STATES, IN USD MILLION (2017–2028)
TABLE 46: GERMANY MARKET SIZE OF CRBSI IN USD MILLION (2017–2028)
TABLE 47: MARKET SIZE OF CRBSI BY THERAPIES IN GERMANY, IN USD MILLION (2017–2028)
TABLE 48: FRANCE MARKET SIZE OF CRBSI IN USD MILLION (2017–2028)
TABLE 49: MARKET SIZE OF CRBSI BY THERAPIES IN FRANCE, IN USD MILLION (2017–2028)
TABLE 50: ITALY MARKET SIZE OF CRBSI IN USD MILLION (2017–2028)
TABLE 51: MARKET SIZE OF CRBSI BY THERAPIES IN ITALY, IN USD MILLION (2017–2028)
TABLE 52: SPAIN MARKET SIZE OF CRBSI IN USD MILLION (2017–2028)
TABLE 53: MARKET SIZE OF CRBSI BY THERAPIES IN SPAIN, IN USD MILLION (2017–2028)
TABLE 54: THE UK MARKET SIZE OF CRBSI IN USD MILLION (2017–2028)
TABLE 55: MARKET SIZE OF CRBSI BY THERAPIES IN THE UK, IN USD MILLION (2017–2028)
TABLE 56: JAPAN MARKET SIZE OF CRBSI IN USD MILLION (2017–2028)
TABLE 57: MARKET SIZE OF CRBSI BY THERAPIES IN THE JAPAN, IN USD MILLION (2017–2028)
LIST OF FIGURES
Figure 1: Types of Central Venous and Arterial Catheter and their sites of insertion
Figure 2: Important pathogenic determinants of catheter-related infections
Figure 3: Potential sources of infection of a percutaneous intravascular device
Figure 4: Total Incident Population of CRBSI in the 7MM (2017–2028)
Figure 5: Total Diagnosed Incident Population of CRBSI in the 7MM (2017–2028)
Figure 6: Diagnosed Incidence of CRBSI by Causative Pathogens in the 7MM (2017–2028)
Figure 7: Total Incident Population of CRBSI in the US (2017–2028)
Figure 8: Total Diagnosed Incident Population of CRBSI in the US (2017–2028)
Figure 9: Diagnosed Incidence of CRBSI by Causative Pathogens in the US (2017–2028)
Figure 10: Total Incident Population of CRBSI in Germany (2017–2028)
Figure 11: Total Diagnosed Incident Population of CRBSI in Germany (2017–2028)
Figure 12: Diagnosed Incidence of CRBSI by Causative Pathogens in Germany (2017–2028)
Figure 13: Total Incident Population of CRBSI in France (2017–2028)
Figure 14: Total Diagnosed Incident Population of CRBSI in France (2017–2028)
Figure 15: Diagnosed Incidence of CRBSI by Causative Pathogens in France (2017–2028)
Figure 16: Total Incident Population of CRBSI in Italy (2017–2028)
Figure 17: Total Diagnosed Incident Population of CRBSI in Italy (2017–2028)
Figure 18: Diagnosed Incidence of CRBSI by Causative Pathogens in Italy (2017–2028)
Figure 19: Total Incident Population of CRBSI in Spain (2017–2028)
Figure 20: Total Diagnosed Incident Population of CRBSI in Spain (2017–2028)
Figure 21: Diagnosed Incidence of CRBSI by Causative Pathogens in Spain (2017–2028)
Figure 22: Total Incident Population of CRBSI in the United Kingdom (2017–2028)
Figure 23: Total Diagnosed Incident Population of CRBSI in the United Kingdom (2017–2028)
Figure 24: Diagnosed Incidence of CRBSI by Causative Pathogens in the United Kingdom (2017–2028)
Figure 25: Total Incident Population of CRBSI in Japan (2017–2028)
Figure 26: Total Diagnosed Incident Population of CRBSI in Japan (2017–2028)
Figure 27: Diagnosed Incidence of CRBSI by Causative Pathogens in Japan (2017–2028)
Figure 28: Flow chart Summarizing Approaches for Systemic Antibiotic Treatment.
Figure 29: Approach to the management of patients with short-term central venous catheter-related or arterial catheter-related bloodstream infection. CFU, colony-forming units; S. aureus, Staphylococcus aureus.
Figure 30: Approach to the treatment of a patient with a long-term central venous catheter (CVC) or a port (P)-related bloodstream infection.
Figure 31: Approach to the treatment of a patient with confirmed CRBSI.
Figure 32: Unmet Needs
Figure 33: Market Size of Catheter-Related Bloodstream Infection (CRBSI) in the 7MM in USD Million (2017–2028)
Figure 34: Market Size of CRBSI by therapies in the 7MM, in USD Million (2017–2028)
Figure 35: Market Size of CRBSI in the US, USD Millions (2017–2028)
Figure 36: Market Size of CRBSI by therapies in the United States, in USD Million (2017–2028)
Figure 37: Market Size of CRBSI in Germany, USD Millions (2017–2028)
Figure 38: Market Size of CRBSI by therapies in Germany, in USD Million (2017–2028)
Figure 39: Market Size of CRBSI in France, USD Millions (2017–2028)
Figure 40: Market Size CRBSI by therapies in France, in USD Million (2017–2028)
Figure 41: Market Size of CRBSI in Italy, USD Millions (2017–2028)
Figure 42: Market Size of CRBSI by therapies in Italy in USD Million (2017–2028)
Figure 43: Market Size of CRBSI in Spain, USD Millions (2017–2028)
Figure 44: Market Size of CRBSI by therapies in Spain in USD Million (2017–2028)
Figure 45: Market Size of CRBSI in the UK, USD Millions (2017–2028)
Figure 46: Market Size of CRBSI by therapies in the UK in USD Million (2017–2028)
Figure 47: Market Size of CRBSI in Japan, USD Millions (2017–2028)
Figure 48: Market Size of CRBSI by therapies in Japan in USD Million (2017–2028)
Figure 49: Market Drivers
Figure 50: Market Barriers
Figure 1: Types of Central Venous and Arterial Catheter and their sites of insertion
Figure 2: Important pathogenic determinants of catheter-related infections
Figure 3: Potential sources of infection of a percutaneous intravascular device
Figure 4: Total Incident Population of CRBSI in the 7MM (2017–2028)
Figure 5: Total Diagnosed Incident Population of CRBSI in the 7MM (2017–2028)
Figure 6: Diagnosed Incidence of CRBSI by Causative Pathogens in the 7MM (2017–2028)
Figure 7: Total Incident Population of CRBSI in the US (2017–2028)
Figure 8: Total Diagnosed Incident Population of CRBSI in the US (2017–2028)
Figure 9: Diagnosed Incidence of CRBSI by Causative Pathogens in the US (2017–2028)
Figure 10: Total Incident Population of CRBSI in Germany (2017–2028)
Figure 11: Total Diagnosed Incident Population of CRBSI in Germany (2017–2028)
Figure 12: Diagnosed Incidence of CRBSI by Causative Pathogens in Germany (2017–2028)
Figure 13: Total Incident Population of CRBSI in France (2017–2028)
Figure 14: Total Diagnosed Incident Population of CRBSI in France (2017–2028)
Figure 15: Diagnosed Incidence of CRBSI by Causative Pathogens in France (2017–2028)
Figure 16: Total Incident Population of CRBSI in Italy (2017–2028)
Figure 17: Total Diagnosed Incident Population of CRBSI in Italy (2017–2028)
Figure 18: Diagnosed Incidence of CRBSI by Causative Pathogens in Italy (2017–2028)
Figure 19: Total Incident Population of CRBSI in Spain (2017–2028)
Figure 20: Total Diagnosed Incident Population of CRBSI in Spain (2017–2028)
Figure 21: Diagnosed Incidence of CRBSI by Causative Pathogens in Spain (2017–2028)
Figure 22: Total Incident Population of CRBSI in the United Kingdom (2017–2028)
Figure 23: Total Diagnosed Incident Population of CRBSI in the United Kingdom (2017–2028)
Figure 24: Diagnosed Incidence of CRBSI by Causative Pathogens in the United Kingdom (2017–2028)
Figure 25: Total Incident Population of CRBSI in Japan (2017–2028)
Figure 26: Total Diagnosed Incident Population of CRBSI in Japan (2017–2028)
Figure 27: Diagnosed Incidence of CRBSI by Causative Pathogens in Japan (2017–2028)
Figure 28: Flow chart Summarizing Approaches for Systemic Antibiotic Treatment.
Figure 29: Approach to the management of patients with short-term central venous catheter-related or arterial catheter-related bloodstream infection. CFU, colony-forming units; S. aureus, Staphylococcus aureus.
Figure 30: Approach to the treatment of a patient with a long-term central venous catheter (CVC) or a port (P)-related bloodstream infection.
Figure 31: Approach to the treatment of a patient with confirmed CRBSI.
Figure 32: Unmet Needs
Figure 33: Market Size of Catheter-Related Bloodstream Infection (CRBSI) in the 7MM in USD Million (2017–2028)
Figure 34: Market Size of CRBSI by therapies in the 7MM, in USD Million (2017–2028)
Figure 35: Market Size of CRBSI in the US, USD Millions (2017–2028)
Figure 36: Market Size of CRBSI by therapies in the United States, in USD Million (2017–2028)
Figure 37: Market Size of CRBSI in Germany, USD Millions (2017–2028)
Figure 38: Market Size of CRBSI by therapies in Germany, in USD Million (2017–2028)
Figure 39: Market Size of CRBSI in France, USD Millions (2017–2028)
Figure 40: Market Size CRBSI by therapies in France, in USD Million (2017–2028)
Figure 41: Market Size of CRBSI in Italy, USD Millions (2017–2028)
Figure 42: Market Size of CRBSI by therapies in Italy in USD Million (2017–2028)
Figure 43: Market Size of CRBSI in Spain, USD Millions (2017–2028)
Figure 44: Market Size of CRBSI by therapies in Spain in USD Million (2017–2028)
Figure 45: Market Size of CRBSI in the UK, USD Millions (2017–2028)
Figure 46: Market Size of CRBSI by therapies in the UK in USD Million (2017–2028)
Figure 47: Market Size of CRBSI in Japan, USD Millions (2017–2028)
Figure 48: Market Size of CRBSI by therapies in Japan in USD Million (2017–2028)
Figure 49: Market Drivers
Figure 50: Market Barriers
